NEW YORK, Nov. 16, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, both dates inclusive (the "Class Period"), have until Friday, December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action lawsuit. Captioned Patel v. Edwards Lifesciences Corporation, No. 24-cv-02221 (C.D. Cal.), the Edwards Lifesciences class action lawsuit c ...

NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

NEW YORK, Nov. 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW).Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=111741&from=4CLASS PERIOD: Febru ...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW). Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=111428&from=3 CLASS PERIO ...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

RADNOR, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against Edwards Lifesciences Corporation (“Edwards”) (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is Dece ...

关于Edwards Lifesciences公司诉讼相关 - 2024年2月6日至2024年7月24日期间购买或收购Edwards Lifesciences公司证券者可在2024年12月13日前寻求成为集体诉讼的首席原告 [1] - 若遭受重大损失并希望成为首席原告可通过指定网址提供信息或联系指定律师 [2] - 该诉讼指控Edwards Lifesciences及其部分高管违反1934年证券交易法 [1] 诉讼指控内容 - 被告在整个期间作出虚假和/或误导性陈述和/或未披露相关信息包括对营收前景和预期增长的虚假印象及对风险的低估等 [4] - TAVR增长有减速风险 [4] - 公司对TAVR增长的乐观报告未达现实因患者激活活动未达预期人群 [4] - 被告过度依赖或夸大医院使用公司TAVR程序的意愿 [4] - 2024年7月24日公司披露第二季度TAVR结果低于预期并下调2024财年预测股价下跌超31% [5] 首席原告相关 - 1995年私人证券诉讼改革法案允许在该期间购买或收购公司证券的投资者寻求成为首席原告 [6] - 首席原告代表所有其他集体成员主导诉讼可选择律所诉讼投资者分享潜在收益不依赖是否为首席原告 [6] 关于Robbins Geller律所 - 是世界领先的代表证券欺诈案投资者的律所之一 [7] - 在ISS证券集体诉讼服务排名过去十年中有六年第一为投资者争取最多金钱救济 [7] - 在证券相关集体诉讼案中为投资者追回66亿美元过去四年比其他律所多22亿美元以上 [7] - 有200名律师分布于10个办公室是世界最大原告律所之一取得过很多历史上最大的证券集体诉讼赔偿 [7]

NEW YORK, Nov. 10, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...